J. Safra Sarasin Holding AG Takes $1.52 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

J. Safra Sarasin Holding AG purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 8,243 shares of the medical research company's stock, valued at approximately $1,522,000.

Other large investors have also recently modified their holdings of the company. Norges Bank bought a new stake in Charles River Laboratories International during the 4th quarter valued at about $98,886,000. Wellington Management Group LLP raised its position in Charles River Laboratories International by 9.0% during the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after purchasing an additional 335,658 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth $42,776,000. Invesco Ltd. grew its position in shares of Charles River Laboratories International by 17.1% during the 4th quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock worth $190,910,000 after buying an additional 151,159 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Charles River Laboratories International by 25.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 663,504 shares of the medical research company's stock valued at $122,482,000 after buying an additional 135,986 shares during the period. Institutional investors own 98.91% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price for the company in a research report on Monday, March 3rd. Barclays decreased their price target on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Robert W. Baird decreased their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $182.00.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Price Performance

CRL traded down $1.05 during trading on Friday, reaching $114.71. 1,516,228 shares of the stock were exchanged, compared to its average volume of 919,695. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of 764.73, a P/E/G ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The business's 50 day moving average price is $146.73 and its two-hundred day moving average price is $171.24.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.46 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).